Memory Th1 cells augment tumor-specific CTL following transcutaneous peptide immunization

Cancer Research

Volumn 68, Issue 10, 2008, Pages 3941-3949

  Hosoi, Akihiro ^a,b   Takeda, Yayoi ^a,b   Furuichi, Yoshihiro ^c   Kurachi, Makoto ^a   Kimura, Kiminori ^a   Maekawa, Ryuji ^b   Takatsu, Kiyoshi ^d   Kakimi, Kazuhiro ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b MEDINET Co Ltd   (Japan)

^c TOKYO MEDICAL UNIVERSITY   (Japan)

^d UNIVERSITY OF TOYAMA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN 85B; CD8 ANTIGEN; CYTOTOXIC T LYMPHOCYTE PEPTIDE; CYTOTOXIC T LYMPHOCYTE PEPTIDE HGP100; EPITOPE; GAMMA INTERFERON; IMIQUIMOD; LYSYLVALYLPROLYLARGINYLASPARAGINYLGLUTAMINYLASPARTYLTRYPTOPHYLLEUCINAMID E; PEPTIDE; PEPTIDE 25; PHENYLALANYLGLUTAMINYLASPARTYLALANYLALANYLGLYCYLGLYCYLHISTIDYLASPARAGINYLVALYLPH ENYLALANINAMIDE; UNCLASSIFIED DRUG;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNIZATION; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DENDRITIC CELL; ENZYME LINKED IMMUNOSPOT ASSAY; IN VIVO STUDY; JAPAN; MEMORY CELL; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; TH1 CELL; TRANSCUTANEOUS PEPTIDE IMMUNIZATION; ANIMAL; C57BL MOUSE; CHEMISTRY; CYTOLOGY; EXPERIMENTAL MELANOMA; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; METABOLISM; MONONUCLEAR CELL; PATHOLOGY; SKIN TUMOR; TRANSGENIC MOUSE; TUMOR CELL LINE;

ADOPTIVE TRANSFER; ANIMALS; CELL LINE, TUMOR; EPITOPES; IMMUNOLOGIC MEMORY; INTERFERON TYPE II; LEUKOCYTES, MONONUCLEAR; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PEPTIDES; SKIN NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC; TH1 CELLS;

EID: 45549087926     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-0032     Document Type: Article

References (31)

1. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004;10:909-15.
2. Almand B, Resser JR, Lindman B, et al. Clinical significance of defective dendritic cell differentiation in cancer. Clin Cancer Res 2000;6:1755-66.
3. + T cells by a novel cell-based artificial APC. Immunol Cell Biol 2006;84:512-21.
4. Glenn GM, Taylor DN, Li X, Frankel S, Montemarano A, Alving CR. Transcutaneous immunization: a human vaccine delivery strategy using a patch. Nat Med 2000;6:1403-6.
5. Rechtsteiner G, Warger T, Osterloh P, Schild H, Radsak MP. Cutting edge: priming of CTL by transcutaneous peptide immunization with imiquimod. J Immunol 2005; 174:2476-80.
6. Suzuki H, Wang B, Shivji GM, et al. Imiquimod, a topical immune response modifier, induces migration of Langerhans cells. J Invest Dermatol 2000;114:135-41.
7. Hemmi H, Kaisho T, Takeuchi O, et al. Small antiviral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol 2002;3:196-200.
8. Stanley MA. Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential. Clin Exp Dermatol 2002;27:571-7.
9. Warger T, Rechtsteiner G, Schmid B, Osterloh P, Schild H, Radsak MP. Transcutaneous immunization with imiquimod is amplified by CD40 ligation and results in sustained cytotoxic T-lymphocyte activation and tumor protection. Clin Rev Allergy Immunol 2007;32:57-66.
10. Gilboa E. DC-based cancer vaccines. J Clin Invest 2007;117:1195-203.
11. + helper T-cell epitopes on mycobacterial antigen in mouse primed with Mycobacterium tuberculosis. Int Immunol 1997;9:227-37.
12. Huygen K, Content J, Denis O, et al. Immunogenicity and protective efficacy of a tuberculosis DNA vaccine. Nat Med 1996;2:893-8.
13. Silver RF, Wallis RS, Ellner JJ. Mapping of T cell epitopes of the 30-kDa α antigen of Mycobacterium bovis strain bacillus Calmette-Guerin in purified protein derivative (PPD)-positive individuals. J Immunol 1995; 154:4665-74.
14. Kamath AT, Feng CG, Macdonald M, Briscoe H, Britton WJ. Differential protective efficacy of DNA vaccines expressing secreted proteins of Mycobacterium tuberculosis. Infect Immun 1999;67:1702-7.
15. + T-cell lines. Infect Immun 2000;68:3933-40.
16. + Th1 cells. Infect Immun 1999;67:4312-9.
17. + cytotoxic T-cell response and antitumour resistance by T helper type 1-inducing peptide. Immunology 2006;117:47-58.
18. + T cells. J Exp Med 2003;198:569-80.
19. Lutz MB, Kukutsch N, Ogilvie AL, et al. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods 1999;223:77-92.
20. Banchereau J, Briere F, Caux C, et al. Immunobiology of dendritic cells. Annu Rev Immunol 2000;18:767-811.
21. Mellman I, Steinman RM. Dendritic cells: specialized and regulated antigen processing machines. Cell 2001; 106:255-8.
22. Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 2004;5: 987-95.
23. Mitsui H, Watanabe T, Saeki H, et al. Differential expression and function of Toll-like receptors in Langerhans cells: comparison with splenic dendritic cells. J Invest Dermatol 2004;122:95-102.
24. Palamara F, Meindl S, Holcmann M, Luhrs P, Stingl G, Sibilia M. Identification and characterization of pDC-like cells in normal mouse skin and melanomas treated with imiquimod. J Immunol 2004;173:3051-61.
25. Heib V, Becker M, Warger T, et al. Mast cells are crucial for early inflammation, migration of Langerhans cells, and CTL responses following topical application of TLR7 ligand in mice. Blood 2007;110:946-53.
26. + T cells: when, where, and how. Annu Rev Immunol 2006;24:519-40.
27. Steinaa L, Rasmussen PB, Wegener AM, et al. Linked foreign T-cell help activates self-reactive CTL and inhibits tumor growth. J Immunol 2005;175:329-34.
28. Calmette A, Plotz H. Protective inoculation against tuberculosis with BCG. Am Rev Tuberc 1929;19:567-72.
29. Andersen P, Doherty TM. The success and failure of BCG - implications for a novel tuberculosis vaccine. Nat Rev Microbiol 2005;3:656-62.
30. Rahman M, Sekimoto M, Takamatsu I, et al. Economic evaluation of universal BCG vaccination of Japanese infants. Int J Epidemiol 2001;30:380-5.
31. Hamaoka T, Takai Y, Kosugi A, et al. The augmentation of tumor-specific immunity using haptenic muramyl dipeptide (MDP) derivatives. I. Synthesis of a novel haptenic MDP derivative cross-reactive with Bacillus Calmette Guerin and its application to enhanced induction of tumor immunity. Cancer Immunol Immunother 1985;20:183-8.